Hearing Outcome of Low-tone Compared to High-tone Sudden Sensorineural Hearing Loss

George Psillas¹  Aikaterini Rizou¹  Dimitrios Rachovitsas¹  Gabriel Tsiropoulos¹  Jiannis Constantinidis¹

¹ 1st Academic ENT Department, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece

Abstract

Introduction  Low-tone sudden sensorineural hearing loss (SSHL) is a well-recognized disease, in which the hearing loss is restricted to low frequencies. In contrast to low-tone SSHL, high-tone SSHL is characterized by high-frequency (4,000, 8,000 Hz) hearing loss and preservation of low-, middle-frequency hearing.

Objective  The objective of this study is to compare the hearing recovery and long-term outcome of low-tone SSHL with those of patients affected by high-tone SSHL in a follow-up of ~3 years.

Methods  The low-tone SSHL and high-tone SSHL groups included 27 and 20 patients, respectively; the patients of both groups were treated with intravenous steroids. Predictive factors (gender, affected side, delay of treatment, follow-up time) were also examined.

Results  Overall, complete hearing recovery was observed in 77.7% of the patients in the low-tone SSHL group and in 15% of the patients in the high-tone SSHL group. In the high-tone SSHL group, a higher proportion of patients reported tinnitus compared with the low-tone SSHL group (13 cases [65%] versus 3 cases [11%]); however, recurrences were more common in the low-tone SSHL (22%, 6 patients) compared with the high-tone SSHL (2 cases [10%]) group. No predictive factor was found to statistically impact on hearing outcome.

Conclusion  After initial therapy, the low-tone SSHL patients have more favorable hearing outcome than high-tone SSHL patients. However, recurrences occurred more frequently in the low-tone SSHL group, while the high-tone SSHL group was more often accompanied by residual symptoms, such as tinnitus.

Introduction

Low-tone sudden sensorineural hearing loss (SSHL) is an already known clinical entity, presenting with low-frequency hearing loss and preservation of high-tone hearing, without vertigo.¹ Abe² described SSHL as an independent disease after studying 39 patients in 1982. Since then, low-tone SSHL was often discussed in Japan and Korea, but less documented in the European or North American studies. The incidence of low-tone SSHL is estimated to be ~40 to 60/100,000 based on Japanese regional surveys.³

On the other hand, high-tone SSHL has not been extensively studied so far, which is characterized by elevation of the thresholds in the high-frequency range and preservation of low-, middle-frequency hearing. In this study, we retrospectively reviewed the records of patients with the diagnosis of low-tone SSHL and compared their hearing thresholds outcome, hearing recovery and long-term symptoms with those of patients affected by high-tone SSHL. Predictive factors affecting the hearing outcome in a follow-up of ~3 years after treatment were also examined.
Methods

The study sample consisted of 47 patients divided into 2 groups, the low-tone SSHL group (27 patients, 10 males, 17 females), and the high-tone SSHL group (20 patients, 8 males, 12 females). The patient characteristics of the two groups are summarized in Table 1. Patients were selected from the low-tone group (125, 250, 500 Hz) and for the high-tone SSHL group (2,000, 4,000 and 8,000 Hz). Administration of steroids and the follow-up period were also statistically studied in relation to the hearing outcome in each group. At the last follow-up, the low-tone SSHL group showed better hearing outcome compared with 15% of cases of the high-tone SSHL group.

For each frequency of pre- and post-treatment, a signiﬁcant difference in hearing level at high frequencies (4,000 and/or 8,000 Hz) was noted within the normal limits on the affected side. Furthermore, each band of frequencies was statistically compared with the initial hearing level, which was always associated with a sensation of loss of auditory acuity, tinnitus or ear fullness and was characterized by at least a 15dB difference in hearing level at high frequencies (4,000 and/or 8,000 Hz) in comparison with that of the healthy side; moreover, hearing thresholds at other frequencies were within the normal limits on the affected side.

Absolute and relative frequencies for all demographic and clinical variables were obtained. All variables were checked for normality via the Kolmogorov-Smirnov test. Non-parametric tests were used where appropriate. Collinearity among scores and other variables in the study was assessed via a correlation matrix, using Pearson r or Spearman r correlation coefficient. The Student t-test or the Mann-Whitney U-test was used for independent sample comparisons. Paired t-test or paired Wilcoxon signed rank test was used for paired comparisons. The Type I error probability was set to 0.05. The statistical analyses were performed using the IBM SPSS Statistics for Windows, version 23.0 package (IBM Corp., Armonk, NY, USA).

Results

The pattern of hearing levels (based on pure tone average at each frequency) of pre and posttreatment is illustrated in Table 1 and 2 for the low-tone and high-tone SSHL groups, respectively. A very statistically signiﬁcant improvement in hearing was found for all low frequencies (125, 250, 500 Hz) in the low-tone SSHL group (Table 2). In the high-tone SSHL group, a signiﬁcant hearing recovery was revealed at 4,000 Hz; however, there was no improvement in hearing at 8,000 Hz (Table 3).

According to Table 4, at the final follow-up, the low-tone SSHL group showed better hearing outcome compared with the high-tone SSHL group. Complete hearing recovery was observed in 77.7% of patients of the low-tone SSHL group compared with 15% of cases of the high-tone SSHL group.

In our study, gender, age, affected side and follow-up period had no statistically signiﬁcant impact on hearing outcome (Table 1); the earlier onset of treatment would possibly affect the hearing recovery in the low-tone group (statistical

| Table 1 Patient characteristics with low- and high-tone sudden sensorineural hearing loss |

<table>
<thead>
<tr>
<th>Gender (males/females)</th>
<th>Age (range in years, mean ± SD)</th>
<th>Side (right/left)</th>
<th>Delay of treatment (range in days, mean ± SD)</th>
<th>Follow-up (in years, mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-tone (n = 27)</td>
<td>10/17</td>
<td>19−72, 44.1 ± 13.1</td>
<td>13/14</td>
<td>0−14; 2.7 ± 3.3</td>
</tr>
<tr>
<td>High-tone (n = 20)</td>
<td>8/12</td>
<td>16−64, 41.4 ± 13.5</td>
<td>11/9</td>
<td>0−60; 8.6 ± 14.2</td>
</tr>
<tr>
<td>Post-treatment</td>
<td>p = 0.537</td>
<td>p = 0.496</td>
<td>p = 0.433</td>
<td>p = 0.089</td>
</tr>
</tbody>
</table>

Abbreviation: SD, standard deviation.
Fig. 1 Audiometric configuration of low-tone sudden sensorineural hearing loss based on average hearing thresholds, pre- and posttreatment, at each frequency (SD: standard deviation).

Fig. 2 Audiometric configuration of high-tone sudden sensorineural hearing loss based on average hearing thresholds, pre- and posttreatment, at each frequency (SD: standard deviation).

Table 2 Low-tone sudden sensorineural hearing loss group; pure tone audiogram average threshold by frequency (dB HL) pre and posttreatment

<table>
<thead>
<tr>
<th>Hz</th>
<th>Pre</th>
<th>Post</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>125</td>
<td>49.44 ± 6.699</td>
<td>20.56 ± 10.860</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>250</td>
<td>48.15 ± 6.954</td>
<td>19.26 ± 10.442</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>500</td>
<td>41.48 ± 10.725</td>
<td>15.93 ± 8.775</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

Table 3 High-tone sudden sensorineural hearing loss group; pure tone audiogram average threshold by frequency (dB HL) pre and posttreatment

<table>
<thead>
<tr>
<th>Hz</th>
<th>Pre</th>
<th>Post</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,000</td>
<td>40.00 ± 24.815</td>
<td>28.25 ± 20.981</td>
<td>0.016</td>
</tr>
<tr>
<td>8,000</td>
<td>64.00 ± 17.137</td>
<td>54.75 ± 21.611</td>
<td>0.081</td>
</tr>
</tbody>
</table>
study, high-tone SSHL was audiometrically characterized by a sensation of loss of auditory acuity. Tone SSHL were quite similar to those in low-tone SSHL, across the frequency band (77.7% versus 15%). The symptoms in high-tone hearing loss in the high-frequency band clearly had contrast to low-tone SSHL. According to the results, patients thresholds elevation restricted to high-frequencies, in contrast to low-tone SSHL (or downward-sloping audiogram), is better than low-tone SSHL (or upward-sloping audiogram) is worse. Most authors have already reported that the prognosis of low-tone SSHL is better than that of high-tone SSHL (or downward-sloping audiogram), although this is not in agreement with other studies. In high-tone SSHL, the hearing recovery was statistically significant after treatment at all frequencies, except at 8,000 Hz (Table 3).}

### Discussion

Most authors have already reported that the prognosis of low-tone SSHL (or upward-sloping audiogram) is better than that of high-tone SSHL (or downward-sloping audiogram), although this is not in agreement with other studies. In our study, high-tone SSHL was audiometrically defined as thresholds elevation restricted to high-frequencies, in contrast to low-tone SSHL. According to the results, patients with hearing loss in the high-frequency band clearly had poorer recovery rates than those with hearing loss in low-frequency band (77.7% versus 15%). The symptoms in high-tone SSHL were quite similar to those in low-tone SSHL, characterized by a sensation of loss of auditory acuity, tinnitus, autophony or fullness in the affected ear; moreover, female preponderance and peak incidence during the fourth decade of life seem to be common in these two clinical entities (Table 1).

Our treatment for low-tone SSHL group was based on intravenous steroid with complete recovery of hearing in 77.7% of patients, which is comparable to the findings of other relatively recent studies. Jung et al found an audiometric improvement rate of 76% with oral steroids alone (follow-up: 8 weeks), which was better than 50% achieved after intratympanic steroid injections alone and 76.9% with combination of the two methods. In a study with almost 2 years of follow-up, Roh et al demonstrated complete hearing improvement in 75% of patients after treatment mainly with oral steroids, which was very close to the results obtained in our last follow-up. However, Morita et al showed lower recovery rates with oral steroid alone (63%) but with 2 months follow-up. It has also been advocated that when diuretics were added to steroids the recovery rates are significantly improved (78.2% to 83.9%).

In high-tone SSHL, the hearing recovery was statistically significant after treatment at all frequencies, except at 8,000 Hz (Table 3). We have no explanation why the treatment for high-tone SSHL is ineffective at 8,000 Hz. It is possible that this region of cochlea at the end portion of the basal turn is most vulnerable to damage, reflecting the gradual downward-sloping hearing loss in presbycusis or ototoxicity with degradation of hearing thresholds at higher frequencies. It has been reported that the levels of glutathione, an antioxidant, tend to be lower at the most basal cochlear turn hair cells and inversely increasing toward the apex; glutathione peroxidase is an enzyme that alter reactive oxygen species to less damaging forms.

The pathophysiological mechanism of low-tone SSHL is still unclear. According to studies, the low-tone SSHL may be a variant of Ménière disease, or the beginning period of Ménière disease. Yamasoba et al, using glycerol test and electrocochleogram (elevated SP/AP ratio), suggested that low-tone SSHL might be caused by endolymphatic hydrops. Fuse et al reported that the etiology of low-tone SSHL involves an autoimmune response of the endolymphatic sac that induces endolymphatic hydrops. On the other side, Choi et al supported that low-tone SSHL might be a different disease entity from Ménière disease, since only 1 among 18 patients who had been checked with electrocochleogram during acute low-tone SSHL showed elevated SP/AP ratio. Moreover, Wu and Young demonstrated that low-tone SSHL should be differentiated from Ménière disease on the basis of vestibular evoked myogenic potentials (VEMPs), since most patients with low-tone SSHL revealed normal VEMPs; in contrast, 50% of Ménière disease patients with low-tone hearing loss showed abnormal VEMPs. In our study, low-tone SSHL progressed to Ménière disease in only 2 (2/27, 7%) patients at 1.5 and 10 years after the SSHL onset. Similarly, Yamashaba et al reported that 5 (11%) out of 45 patients followed up for more than 3 years developed Ménière disease. Compared with low-tone SSHL cases, our patients with high-tone SSHL did not develop Ménière disease, although initially there were a few complaints of lightheadedness and instability. It seems that low-tone SSHL is not the same disease as Ménière disease because a limited proportion of low-tone SSHL cases progressed to Ménière disease.

However, recurrences occurred more frequently in the low-tone SSHL (22%) than in the high-tone SSHL group (10%). It has been postulated that patients with low-tone SSHL.

### Table 4 Hearing recovery at the last follow-up in low- and high-tone sudden sensorineural hearing loss

<table>
<thead>
<tr>
<th></th>
<th>Complete</th>
<th>Partial</th>
<th>Unchanged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-tone (n = 27)</td>
<td>21 (77.7%)</td>
<td>3 (11.1%)</td>
<td>3 (11.1%)</td>
</tr>
<tr>
<td>High-tone (n = 20)</td>
<td>3 (15%)</td>
<td>6 (30%)</td>
<td>11 (55%)</td>
</tr>
</tbody>
</table>

Note: The low-tone sudden sensorineural hearing loss group showed better hearing outcome compared with the high-tone sudden sensorineural hearing loss group (Pearson Chi-squared test, p < 0.001)
suffering of recurrent episodes of hearing loss tended to have endolymphatic hydrops (higher summation potential/action potential [SP/AP] ratio of electrocochleography), whereas those without recurrent episodes do not. According to previous reports, the incidence of recurrences after low-tone SSHL onset has ranged from 9 to 45%, the majority of them were documented within one year of the first attack. Indeed, Oishi et al supported that if the low-tone SSHL patients display hearing fluctuations within one year after the initial attack, about half of them exhibited high- and pan-frequency hearing loss within 10 years of onset; nevertheless, with regard to progression of hearing loss at high frequencies we should consider the effect of aging.

In both groups, no factors such as gender, age, affected side, follow-up period, hearing thresholds at each frequency pre and posttreatment have been found to be significant in prognosis. The earlier onset of treatment would possibly affect the hearing recovery in the low-tone SSHL group (statistical trend). In addition, a prompt treatment with steroids within 2 days from the onset of low- or high-tone SSHL was not apparently related to the prognosis of low frequency sensorineural hearing loss (statistical trend). In addition, a prompt treatment with steroids within 2 days from the onset of low- or high-tone SSHL was not apparently related to the absolute recovery in the low-tone SSHL group (statistical trend). In addition, a prompt treatment with steroids within 2 days from the onset of low- or high-tone SSHL was not apparently related to the absolute recovery in the low-tone SSHL group (statistical trend).

**Conclusion**

High-tone SSHL, which is characterized by hearing loss at high frequencies, shows poor recovery rates and residual symptoms, such as tinnitus; low-tone SSHL has a more favorable hearing outcome but is more often associated with recurrences and less commonly progressed to Ménière disease. Further studies are needed, as well as more extensive research, to better understand the etiology of both low- and high-tone SSHL.

**References**